Anti-IL-6 Receptor Nanobody (ALX-0061) Seamless "First-in-Human" Phase I/II POC Study in Patients with Active RA On Stable MTX Treatment

被引：0
|
作者：
De Bruyn, Steven [1 ]
Gachalyi, Bela [2 ]
Rojkovich, Bernadette [3 ]
Bruk, Slavomir [4 ]
Sramek, Petr [5 ]
Korkosz, Mariusz [6 ]
Krause, Krzysztof [7 ]
Schoen, Pieter [1 ]
Sargentini-Maier, Laura [1 ]
D'Artois, Joke [1 ]
Verschueren, Katrien [1 ]
De Swert, Katelijne [1 ]
Arold, Gerhard [8 ]
Holz, Josefin-Beate [1 ]
机构：
[1] Ablynx NV, Zwijnaarde, Belgium
[2] Peterfy Sandor Utcai Korhaz, Budapest, Hungary
[3] Budai Irgalmasrendi Korhaz Kht, Budapest, Hungary
[4] Nemocnice Trinec, Trinec, Czech Republic
[5] Pharmaceut Res Associates CZ, Prague, Czech Republic
[6] Szpital Uniwersytecki Krakowie, Krakow, Poland
[7] Wojewodzki Szpital, Wroclaw, Poland
[8] PRA Int GmbH, Berlin, Germany
来源：
ARTHRITIS AND RHEUMATISM | 2012年 / 64卷 / 10期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
1307
引用
收藏
页码：S561 / S561
页数：1
相关论文
共 31 条
  • [1] TWENTY-FOUR WEEKS OF TREATMENT WITH A NOVEL ANTI-IL-6 RECEPTOR NANOBODY® (ALX-0061) RESULTED IN 84% ACR20 IMPROVEMENT AND 58% DAS28 REMISSION IN A PHASE I/II STUDY IN RA
    Holz, J. -B.
    Sargentini-Maier, L.
    De Bruyn, S.
    Gachalyi, B.
    Udvaros, I.
    Rojkovich, B.
    Bruk, S.
    Sramek, P.
    Korkosz, M.
    Krause, K.
    Schoen, P.
    D'Artois, J.
    Verschueren, K.
    Willems, W.
    De Swert, K.
    Arold, G.
    ANNALS OF THE RHEUMATIC DISEASES, 2013, 72 : 64 - 64
  • [2] Tocilizumab (Anti-IL-6 Receptor Antibody) and Intravenous Immunoglobulin (IVIG) in Difficult To Desensitize Patients: Phase I/II Trial
    Vo, Ashley
    Kim, Jua
    Kim, Irene
    Jordan, Stanley
    AMERICAN JOURNAL OF TRANSPLANTATION, 2015, 15 : 49 - 49
  • [3] A Phase I/II Trial of Tocilizumab (Anti-IL-6 Receptor) plus Intravenous Immunoglobulin (IVIG) for Desensitization (DES) in Difficult to DES Patients
    Vo, A.
    Choi, J.
    Cisneros, K.
    Kahwaji, J.
    Toyoda, M.
    Bongha, S.
    Ge, S.
    Peng, A.
    Villicana, R.
    Jordan, S.
    AMERICAN JOURNAL OF TRANSPLANTATION, 2014, 14 : 103 - 103
  • [4] A Phase I/II Trial of Tocilizumab (Anti-IL-6 Receptor) plus Intravenous Immunoglobulin (IVIG) for Desensitization (DES) in Difficult to DES Patients
    Vo, A.
    Choi, J.
    Cisneros, K.
    Kahwaji, J.
    Toyoda, M.
    Bongha, S.
    Ge, S.
    Peng, A.
    Villicana, R.
    Jordan, S.
    TRANSPLANTATION, 2014, 98 : 103 - 103
  • [5] SAFETY, TOLERABILITY, PHARMACOKINETICS AND PHARMACODYNAMICS OF BCD-089, NOVEL MONOCLONAL ANTI-IL-6 RECEPTOR ANTIBODY: RESULTS FROM THE FIRST-IN-HUMAN SINGLE DOSE ESCALATION STUDY IN HEALTHY VOLUNTEERS
    Khlyabova, P.
    Eremeeva, A.
    Lutckii, A.
    Dokukina, E.
    Chemyaeva, E.
    Ivanov, R.
    ANNALS OF THE RHEUMATIC DISEASES, 2018, 77 : 884 - 885
  • [6] Anti-IL21 Receptor Monoclonal Antibody (ATR-107): Safety, Pharmacokinetics, and Pharmacodynamic Evaluation in Healthy Volunteers: A Phase I, First-in-Human Study
    Hua, Fei
    Comer, Gail M.
    Stockert, Lori
    Jin, Bo
    Nowak, John
    Pleasic-Williams, Susan
    Wunderlich, David
    Cheng, John
    Beebe, Jean S.
    JOURNAL OF CLINICAL PHARMACOLOGY, 2014, 54 (01): : 14 - 22
  • [7] A First-in-Human Phase I Study of GC1118, a Novel Anti-Epidermal Growth Factor Receptor Antibody, in Patients with Advanced Solid Tumors
    Oh, Do-Youn
    Lee, Keun-Wook
    Han, Sae-Won
    Kim, Jin Won
    Shin, Jung-Won
    Jo, Seong-Jin
    Won, Jonghwa
    Hahn, Seokyung
    Lee, Howard
    Kim, Woo Ho
    Bang, Yung-Jue
    ONCOLOGIST, 2019, 24 (08): : 1037 - +
  • [8] SATISFY-JP, a phase II multicenter open-label study on Satralizumab, an anti-IL-6 receptor antibody, use for the treatment of pulmonary arterial hypertension in patients with an immune-responsive-phenotype: Study protocol
    Tamura, Yuichi
    Takeyasu, Rika
    Takata, Tomohiro
    Miyazaki, Naoki
    Takemura, Ryo
    Wada, Michihiko
    Tamura, Yudai
    Abe, Kohtaro
    Shigeta, Ayako
    Taniguchi, Yu
    Adachi, Shiro
    Inami, Takumi
    Tsujino, Ichizo
    Tahara, Nobuhiro
    Kuwana, Masataka
    PULMONARY CIRCULATION, 2023, 13 (02)
  • [9] Efficacy and safety of tocilizumab in monotherapy, an anti-IL-6 receptor monoclonal antibody, in patients with active rheumatoid arthritis: Results from a 24 week double-blind phase III study
    Nishimoto, N.
    Miyasaka, N.
    Yamamoto, K.
    Kawai, S.
    Takeuchi, T.
    Azuma, J.
    Kishimoto, T.
    ANNALS OF THE RHEUMATIC DISEASES, 2006, 65 : 59 - 59
  • [10] First-in-human phase I/II, open-label study of the anti-OX40 agonist INCAGN01949 in patients with advanced solid tumors
    Davis, Elizabeth J.
    Martin-Liberal, Juan
    Kristeleit, Rebecca
    Cho, Daniel C.
    Blagden, Sarah P.
    Berthold, Dominik
    Cardin, Dana B.
    Vieito, Maria
    Miller, Rowan E.
    Dass, Prashanth Hari
    Orcurto, Angela
    Spencer, Kristen
    Janik, John E.
    Clark, Jason
    Condamine, Thomas
    Pulini, Jennifer
    Chen, Xuejun
    Mehnert, Janice M.
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2022, 10 (10)
1234